about
High-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methodsThe development of low-grade cerebral edema in cirrhosis is supported by the evolution of (1)H-magnetic resonance abnormalities after liver transplantation.Isolated bilateral Tapia's syndrome after liver transplantation: A case report and review of the literature.Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry.Cirrhosis, liver transplantation and HIV infection are risk factors associated with hepatitis E virus infectionEvolution and management of de novo neoplasm post-liver transplantation: a 20-year experience from a single European centreIncreased tumour necrosis factor alpha production in mesenteric lymph nodes of cirrhotic patients with ascitesAnalysis of adult 20-year survivors after liver transplantationThe effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver diseaseVisceral leishmaniasis among liver transplant recipients: an overview.Safety of liver transplantation with Chagas disease-seropositive donors for seronegative recipients.Transjugular intrahepatic portosystemic shunt for the treatment of sinusoidal obstruction syndrome in a liver transplant recipient and review of the literature.Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation.Successful Continuation of HCV Treatment After Liver Transplantation.Human immunodeficiency virus-infected liver transplant recipients with incidental hepatocellular carcinoma: A prospective multicenter nationwide cohort study.Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C.Efficacy and Safety of Therapy With Simeprevir and Sofosbuvir in Liver Transplant Recipients Infected by Hepatitis C Virus Genotype 4: Cohort Spanish Society of Liver Transplantation Cohort.Performance, ruminal changes, behaviour and welfare of growing heifers fed a concentrate diet with or without barley straw.Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multicenter cohort study.High HCV subtype heterogeneity in a chronically infected general population revealed by high-resolution hepatitis C virus subtyping.Predictive model of mortality in patients with spontaneous bacterial peritonitis.Correction for Quer at al., High-Resolution Hepatitis C Virus Subtyping Using NS5B Deep Sequencing and Phylogeny, an Alternative to Current Methods.Treatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir-based therapy.Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma.Impact of Cytomegalovirus Infection on Severe Hepatitis C Recurrence in Patients Undergoing Liver Transplantation.Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation.Hemoperitoneum as a first manifestation of hepatocellular carcinoma in western patients with liver cirrhosis: effectiveness of emergency treatment with transcatheter arterial embolization.Hepatitis B virus quasispecies evolution after liver transplantation in patients under long-term lamivudine prophylaxis with or without hepatitis B immune globulin.Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study.Early predictors of antiviral treatment response in liver transplant recipients with recurrent hepatitis C genotype 1.Liver biopsy-related infection in liver transplant recipients: A current matter of concern?Twelve-week posttreatment follow-up to predict sustained virologic response for recurrent hepatitis C infection in liver recipients.Recurrent hepatitis C virus infection after liver transplantation: immunohistochemical assessment of the viral antigen.Imaging of hepatitis C virus infection in liver grafts after liver transplantation.Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation.Long-term outcome of hepatitis C virus infections acquired after pediatric liver transplantation.Evaluation of Anti-HBs serum levels and pharmacokinetic profile after intravenous administration of Niuliva, a new hepatitis B immunoglobulin, following liver transplantation.Indications and management of everolimus after liver transplantation.A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma.
P50
Q28652352-5926BB05-41AC-4F68-9819-5739C0F4E2A1Q30664814-40D70321-1745-458B-A8A2-D4B91B38E9ACQ31154492-05D20665-F68A-4844-8EA3-BCE11E00486DQ31160142-C0612689-BF47-41BD-82DF-EED9CAD8FD73Q33961593-569177FB-009F-4DE7-8ABE-B3BFBB6FD30BQ34959580-5E0F36D4-E455-4CB2-92F7-0EF1CD651B55Q35595814-CBA40005-7D7B-41E5-ABF4-BE59EFD62AB4Q35757871-F1380ECF-F55E-40F8-A62A-3DDA9C394855Q36243096-DA54D92F-7D6B-41CD-BC65-34FF827F2E78Q37331906-2B1877D7-2CC6-45E8-8091-2E92BF796AA0Q37880745-6B74C9B1-30E8-4547-9065-532D18E38039Q37886889-1476B538-F5DF-4ADD-895D-E0A468296318Q38607787-7F2A9C5F-D826-495F-A728-9BCD5B4395CDQ38788550-DE566996-5F71-4AAA-9F5C-A881DE4DF942Q38966325-D711C04A-D200-4049-AC79-3CC91919C6DAQ39007700-FB2C443F-471E-4499-8325-02A1C130310CQ39049269-A09229F0-09BF-44EE-84A9-DD4C6DD1F348Q39118348-F50BF64D-4A71-4821-BC5B-52AFFCDDCCF8Q40027403-72B65712-B85D-4E8B-A80E-53A37B5718E9Q40162171-0D3589C7-3D92-4A75-9DFA-55366A8D1D6AQ40335058-3ECB6278-2369-4A9A-B747-F13CB433D582Q40597812-F6CE5BBC-C117-4C95-A1ED-3A78CDCB0B3DQ40682456-582CBFEE-CAA9-4969-9853-84EA6DDEF49BQ40705980-BB170817-E4E1-46EA-812F-0AAB57CC0B5EQ40931102-904AC261-45CD-4649-A2AD-F49FD74E0EDEQ40999338-1A44D237-B0D3-4862-B027-2FC23A95862FQ41564280-29ED8741-69C1-4BA9-A380-88BBBD122DC3Q42045469-557BF182-FFE3-4392-8388-B4056457C83BQ42173073-94FC8D3F-ACD3-4A3C-AC93-0590D89B2649Q42199725-E9E86F84-B3DB-4D11-93B9-2C3D33104889Q42232115-40352C71-2C39-45EF-8C4E-2D30D438B670Q42233966-B28A52D3-2C2F-4A3F-AF37-A643EB0F2242Q42977026-92E348FB-3632-46A0-B387-DB77CD8BBE8EQ42988839-FA5B39BA-07BE-4946-AEC3-C0CEB0419B70Q42990765-8DF96188-9894-43FD-A225-6296B4E6500DQ42992260-7E86D1AF-7005-456E-9A64-0715CACFCE8BQ43040672-3C579A1D-DE24-4DC6-B157-A164F4BACA92Q43224172-5208B539-90B3-4C59-BBCF-0C2847F17107Q43284025-25E2030F-D001-4103-AB96-D14C44852B70Q43660230-C2F36B64-F4C2-495C-8EE0-1BC490B69F42
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Lluís Castells
@ast
Lluís Castells
@en
Lluís Castells
@es
Lluís Castells
@nl
type
label
Lluís Castells
@ast
Lluís Castells
@en
Lluís Castells
@es
Lluís Castells
@nl
prefLabel
Lluís Castells
@ast
Lluís Castells
@en
Lluís Castells
@es
Lluís Castells
@nl
P106
P1153
7003874060
P21
P31
P496
0000-0002-6672-5931